Natarajan Sethuraman Sells 2,642 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78. Following the completion of the transaction, the insider now owns 183,816 shares of the company’s stock, valued at $2,773,783.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.24, for a total transaction of $9,144.00.
• On Monday, July 15th, Natarajan Sethuraman sold 638 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $11,484.00.
• On Friday, July 12th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $10,800.00.

Entrada Therapeutics Stock Up 1.0 %

Shares of NASDAQ TRDA opened at $14.86 on Thursday. The firm has a 50-day simple moving average of $16.04 and a 200-day simple moving average of $14.66. The stock has a market capitalization of $501.66 million, a price-to-earnings ratio of 23.59 and a beta of -0.24. Entrada Therapeutics, Inc. has a 52 week low of $10.75 and a 52 week high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million during the quarter, compared to analysts’ expectations of $55.00 million. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 0.68 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds have recently modified their holdings of TRDA. New York State Teachers Retirement System purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at about $27,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the first quarter valued at about $79,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares during the period. Rhumbline Advisers grew its holdings in shares of Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after purchasing an additional 7,452 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Entrada Therapeutics in the second quarter valued at about $636,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TRDA shares. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 14th. Oppenheimer restated an “outperform” rating and set a $25.00 price objective on shares of Entrada Therapeutics in a research report on Monday, August 26th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.